Research Analysts Offer Predictions for IOVA FY2027 Earnings

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) – Investment analysts at Zacks Research issued their FY2027 earnings per share (EPS) estimates for Iovance Biotherapeutics in a research note issued on Wednesday, March 19th. Zacks Research analyst S. Ganoria expects that the biotechnology company will earn $0.13 per share for the year. The consensus estimate for Iovance Biotherapeutics’ current full-year earnings is ($1.24) per share.

Iovance Biotherapeutics (NASDAQ:IOVA) last announced its quarterly earnings data on Thursday, February 27th. The biotechnology company reported ($0.26) earnings per share for the quarter, meeting the consensus estimate of ($0.26). The business had revenue of $73.69 million during the quarter, compared to analyst estimates of $72.17 million. Iovance Biotherapeutics had a negative return on equity of 58.43% and a negative net margin of 451.25%.

Several other brokerages have also weighed in on IOVA. Truist Financial cut their price objective on Iovance Biotherapeutics from $25.00 to $15.00 and set a “buy” rating for the company in a report on Monday, March 3rd. Robert W. Baird cut their target price on Iovance Biotherapeutics from $24.00 to $20.00 and set an “outperform” rating on the stock in a research report on Friday, February 28th. The Goldman Sachs Group cut their target price on Iovance Biotherapeutics from $22.00 to $19.00 and set a “buy” rating on the stock in a research report on Monday, March 3rd. Piper Sandler cut their target price on Iovance Biotherapeutics from $7.50 to $6.00 and set a “neutral” rating on the stock in a research report on Friday, February 28th. Finally, Chardan Capital cut their target price on Iovance Biotherapeutics from $34.00 to $30.00 and set a “buy” rating on the stock in a research report on Monday, March 3rd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $20.25.

Iovance Biotherapeutics Price Performance

Shares of Iovance Biotherapeutics stock opened at $3.54 on Friday. The firm has a market cap of $1.16 billion, a price-to-earnings ratio of -2.38 and a beta of 0.93. The business has a fifty day simple moving average of $5.12 and a 200-day simple moving average of $7.77. Iovance Biotherapeutics has a fifty-two week low of $3.42 and a fifty-two week high of $15.50.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. California State Teachers Retirement System raised its position in Iovance Biotherapeutics by 7.3% during the fourth quarter. California State Teachers Retirement System now owns 203,241 shares of the biotechnology company’s stock valued at $1,504,000 after buying an additional 13,774 shares during the period. Arcadia Wealth Management Inc. acquired a new position in Iovance Biotherapeutics during the fourth quarter valued at $117,000. B. Riley Wealth Advisors Inc. raised its position in Iovance Biotherapeutics by 39.4% during the fourth quarter. B. Riley Wealth Advisors Inc. now owns 19,442 shares of the biotechnology company’s stock valued at $144,000 after buying an additional 5,500 shares during the period. GF Fund Management CO. LTD. acquired a new position in Iovance Biotherapeutics during the fourth quarter valued at $47,000. Finally, Neo Ivy Capital Management acquired a new position in Iovance Biotherapeutics during the fourth quarter valued at $3,353,000. 77.03% of the stock is owned by institutional investors and hedge funds.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.